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Abstract 
Purpose: Occult hepatitis B infection (OBI) among HIV positive patients varies widely in different geographic regions. 
We undertook a study to determine the prevalence of occult hepatitis B infection among HIV infected individuals 
visiting a health facility in South West Cameroon and characterized occult HBV strains based on sequence analyses.
Methods: Plasma samples (n = 337), which previously tested negative for hepatitis B surface antigen (HBsAg), were 
screened for antibodies against hepatitis B core (anti-HBc) and surface (anti-HBs) antigens followed by DNA extrac-
tion. A 366 bp region covering the overlapping surface/polymerase gene of HBV was then amplified in a nested PCR 
and the amplicons sequenced using Sanger sequencing. The resulting sequences were then analyzed for genotypes 
and for escape and drug resistance mutations.
Results: Twenty samples were HBV DNA positive and were classified as OBI giving a prevalence of 5.9%. Out of these, 
9 (45%) were anti-HBs positive, while 10 (52.6%) were anti-HBc positive. Additionally, 2 had dual anti-HBs and anti-HBc 
reactivity, while 6 had no detectable HBV antibodies. Out of the ten samples that were successfully sequenced, nine 
were classified as genotype E and one as genotype A. Three sequences possessed mutations associated with lamivu-
dine resistance. We detected a number of mutations within the major hydrophilic region of the surface gene where 
most immune escape mutations occur.
Conclusions: Findings from this study show the presence of hepatitis B in patients without any of the HBV serologi-
cal markers. Further prospective studies are required to determine the risk factors and markers of OBI.
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Background
Hepatitis B, a potentially life-threatening liver infection 
caused by the hepatitis B virus (HBV) is a major global 
health problem. Of the two billion people infected with 
the virus, more than 240 million are chronic carriers [1], 
and more than 686,000 die annually from HBV-related 
complications, including cirrhosis and hepatocellular 
carcinoma [2]. A growing body of evidence is emerg-
ing showing that the prevalence of HBV is significantly 
higher amongst HIV-positive individuals, presumably 
because of the shared transmission risks and risk factors 
[3, 4]. HIV generally accelerates the natural course of 
HBV infection and facilitates faster progression of liver 
disease to cirrhosis and hepatocellular carcinoma (HCC) 
[5].
Traditionally, HBV is diagnosed by serological tech-
niques to detect antigens or antibodies. The hepatitis B 
surface antigen (HBsAg) is often used for routine diag-
nosis since it is considered as the hallmark of infection. 
During acute infection, antibodies to HBV core antigens 
(anti-HBc) (initially both IgM and IgG) appear 1–2 weeks 
after the appearance of HBsAg, while IgG persists during 
Open Access
AIDS Research and Therapy
*Correspondence:  bessong@univen.ac.za; pascal.bessong@gmail.com 
1 HIV/AIDS & Global Health Research Program, Department 
of Microbiology, University of Venda, Private Bag X5050, 
Thohoyandou 0950, Limpopo, South Africa
Full list of author information is available at the end of the article
Page 2 of 7Gachara et al. AIDS Res Ther  (2017) 14:11 
chronic infection. The presence of antibodies to HBsAg 
(anti-HBs) represents immunity to HBV infection [6].
In the advent of molecular diagnostics, it has been 
shown that a number of individuals may harbour HBV-
DNA at very low levels in their liver and/or serum despite 
the absence of detectable HBsAg by currently available 
assays [7]. This is termed occult hepatitis B infection 
(OBI), characterized by the presence of HBV DNA in 
the blood and liver in HBsAg-negative individuals, who 
may or may not have anti-HBc and anti-HBs [6]. There 
are several mechanisms that have been hypothesized to 
lead to development of OBI. These include development 
of HBV S gene mutants that affect the detectability of the 
virus by conventional HBsAg assays, strong suppression 
of viral replication and reduced expression of HBsAg, 
epigenetic mechanisms and co-infection with other 
viruses [8].
OBI is frequent in persons with HIV, and its prevalence 
varies considerably in different geographic regions [9]. 
It has been shown that immunosuppression due to HIV 
infection could lead to low antibody response to HBsAg 
and also HBV reactivation [10, 11]. Consequently, among 
HIV patients who test HBsAg negative, HBV DNA should 
be determined before starting highly active antiretroviral 
therapy (HAART) so that anti-HBV antiretrovirals can be 
included if necessary. The prevalence of OBI however, has 
been shown to vary in different demographic settings. A 
recent study in Cameroon reporting on OBI focused on 
patients from a health centre in the capital Yaoundé [12]. 
It would be expected therefore that the two regions of 
Cameroon from where the patients in the current study 
were derived would provide added information on OBI in 
this country where both HBV and HIV are endemic.
Methods
Study design and setting
This was a cross-sectional retrospective study using 337 
HBsAg negative plasma samples from 455 HIV posi-
tive outpatient clients of the Mutengene Baptist Health 
Centre located in the South West Region of Cameroon. 
The health centre offers HIV/AIDS treatment, preven-
tion, medical, spiritual and psychosocial care in the Tiko 
Health District. The hospital attends to at least 8000 
patients per month. Patients come from various towns 
such as Buea, Limbe, Tiko, Kumba in the South West 
Region, and Douala, Nkongsamba, in the Littoral Region. 
Details of the study setting have been reported [13].
Sample collection and processing
All consenting participants completed a questionnaire 
regarding their socio-demographic characteristics. Five 
millilitres of venous blood was collected once from each 
consenting HIV positive adult individual using EDTA 
vacutainer tubes while two ml of blood was collected 
from young children (<5  years). Blood was centrifuged 
for 5  min at 3578×g. Following centrifugation, plasma 
was aspirated aseptically and aliquoted into sterile 
labelled cryotubes and stored at −80 °C. These were then 
transported on dry ice to the HIV/AIDS & Global Health 
Research laboratories at the University of Venda, South 
Africa where they were stored at −80 °C until used.
Serological testing
Initially, all samples were screened for HBsAg using a 
commercially available direct enzyme-linked immuno-
sorbent assay (ELISA) kit (Bioelisa, Biokit, Barcelona, 
Spain). In this study, samples that were HBsAg nega-
tive were further screened for anti-HBc and anti-HBs 
using another ELISA commercial kit (DRG Instruments 
GmbH, Germany).
DNA extraction
DNA from HBsAg negative samples was extracted from 
100  µl of plasma using the Quick-gDNA mini prep kit 
(Zymo research, USA) according to the manufacturer’s 
instructions. The extracted DNA was amplified immedi-
ately after extraction or stored at −20 °C awaiting subse-
quent amplification.
Polymerase chain reaction (PCR) for HBV surface/
polymerase gene
A nested PCR was performed in order to amplify the 
overlapping surface/polymerase gene covering nucleo-
tides 403–768 from the EcoR1 site using primers and 
protocols described previously [14]. This generates a 
366  bp product (Additional file  1: Figure S1). The first 
round reaction was conducted in a 50 µl volume contain-
ing 10 mM Tris-HCI pH 8.3, 50 mM potassium chloride, 
0.2 mM dNTP mix, 2.5 mM magnesium chloride, 0.2 ng/
µl of each primer, and 2 units of Taq polymerase (Applied 
Biosystems, PE, Italia). The thermocycling conditions 
involved 35 cycles of denaturation at 95  °C for 1  min, 
annealing at 55  °C for 1 min, and extension at 72  °C for 
1 min. Five microlitre of the first round PCR product was 
used as a template for the nested PCR under the same 
reaction conditions, but performing only 20 cycles. The 
PCR products were then resolved by 1.5% agarose gel 
electrophoresis stained with ethidium bromide. PCR 
amplicons were then purified using the QiAquick PCR 
Purification Kit (Qiagen, Hilden; Germany) according to 
the manufacturer’s instructions.
Sequencing and sequence analysis
Purified PCR amplicons were directly sequenced at 
Inqaba Biotech (Pretoria, South Africa) according to 
the Sanger protocol. Contiguous nucleotide sequences 
Page 3 of 7Gachara et al. AIDS Res Ther  (2017) 14:11 
(contigs) were assembled from resulting forward and 
reverse reactions using the SeqMan Pro® module of the 
Lasergene (version 8.1.5) sequence analysis software suite 
(DNASTAR. Madison, WI.).
The resulting nucleotide sequences were aligned using 
the Clustal W program implemented in MEGA 6.06 [15]. 
They were also translated and checked for HBsAg muta-
tions in the S gene and drug resistance associated muta-
tions in the P gene. Phylogenetic reconstruction was 
carried out using the MrBayes program version 3.1.2 [16]. 
The Bayesian tree was inferred by running a Markov-
chain Monte Carlo (MCMC) algorithm for 1 million gen-
erations, sampling at every 100th generation with a burn 
in setting of 10% of generations. The GTR+G+I model 
(general time-reversible model with gamma distributed 
rates of variation among sites and a proportion of invari-
able sites) was found to be the best-fit model for our 
dataset. The resulting phylogenetic tree was visualized 
using FigTree, version 1.3.1 (http://tree.bio.ed.ac.uk/soft-
ware/figtree/) and used to determine the HBV genotype.
Statistical analysis
A database was prepared and processed using SPSS 20 
(IBM, Chicago, IL, USA). Fisher’s exact test was used to 
analyze the socio-demographic and clinical variables 
associated with OBI. A p value of less than 0.05 was con-
sidered statistically significant.
Results
Prevalence of occult HBV infection
HBV DNA was detected in 20 out of the 337 HBsAg 
negative samples giving an OBI prevalence of 5.9% in this 
study. OBI was higher among females, the unemployed, 
patients with low hemoglobin, those with normal white 
blood cell count and malaria negative individuals. How-
ever none of these variables were statistically associated 
with OBI (Table 1).
Serological profile of occult HBV infection
All the study samples were assayed for anti-HBs and 
anti-HBc serological markers. Out of the OBI positive 
samples, 9 (45%) were anti-HBs positive while 10 (52.6%) 
were anti-HBc positive (Table  2). Additionally, 2 indi-
viduals had dual anti-HBs and anti-HBc reactivity while 6 
had no detectable HBV antibodies.
Molecular and genetic characterization of occult HBV DNA
Sequencing of the overlapping surface/polymerase gene 
was done for 10 out of the 20 OBI positive DNA sam-
ples. Phylogenetic analyses indicated that HBV geno-
type E and A occurred in 9 (90%) and 1 (10%) individuals 
respectively (Fig. 1).
Mutations in the “a” determinant within the major 
hydrophilic region (MHR) of the S gene may cause a 
conformational change in HBsAg, leading to undetect-
ability of HBsAg (diagnostic-escape) as well as evading 
Table 1 The prevalence of  occult hepatitis B infection 
(OBI), demographic variables, and  associated risk factors 
among HIV/HBV infected patients in Cameroon
Variable OBI negative (%) OBI positive (%) p value
Gender 0.303
 Male 85 (26.8) 3 (15.0)
 Female 232 (73.2) 17 (85.0)
Age-group (years) 0.382
 <15 30 (9.5) 4 (20.0)
 15–24 14 (4.4) 0 (0.0)
 25–35 140 (44.2) 6 (30.0)
 36–45 85 (26.8) 6 (30.0)
 >45 48 (15.1) 4 (20.0)
Employment status 0.776
 Employed 67 (21.1) 3 (15.0)
 Unemployed 250 (78.9) 17 (85.0)
Malaria infection 1.00
 Malaria positive 107 (33.8) 7 (35.0)
 Malaria negative 210 (66.2) 13 (65.0)
WHO clinical stage 0.179
 Stage 1 67 (21.7) 3 (15.0)
 Stage 2 87 (28.1) 7 (35.0)
 Stage 3 100 (32.4) 7 (35.0)
 Stage 4 55 (17.8) 3 (15.0)
CD4 count 1.00
 <350 174 (54.9) 11 (45.0)
 >350 143 (45.1) 9 (55.0)
Haemoglobin level 1.00
 Low Hb 220 (69.4) 14 (70.0)
 Normal Hb 97 (30.6) 6 (30.0)
White blood cell count 0.193
 Low WBC count 82 (25.9) 8 (40.0)
 Normal WBC count 235 (74.1) 12 (60.0)
Table 2 Serological characterization of  OBI individuals 
among HIV/HBV infected patients in Cameroon
a This was done for 324 patients due to insufficient sample volume
b This was done for 329 patients due to insufficient sample volume
c There was insufficient sample volume to conduct both anti-HBs and anti-HBc 
screening for one patient who was OBI positive
OBI status Anti-HBs statusa Anti-HBc statusb
Anti-HBs+ Anti-HBs− Anti-HBc+ Anti-HBc−
OBI positivec 5 14 10 9
OBI negative 104 201 176 134
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the host’s immune response (immune-escape). The main 
mutation observed in this region was the G159A muta-
tion observed in eight (80%) of the samples compared 
to 41.3% among HBsAg positive samples previously 
observed. Also, nine of the samples possessed leucine at 
amino acid 127. Examination of the RT domain of the 
polymerase gene indicated that three of the sequences 
had mutations associated with drug resistance. These 
mutations V173L, L180M, T184S and M204V/I are 
associated with resistance to lamivudine, entecavir and 
telbivudine (Fig.  2). The three patients harboring these 
mutations had treatment experience with Lamivudine as 
part of their antiretroviral therapy.
Discussion
Laboratory detection of Hepatitis B virus infection is 
crucial for global control and prevention of HBV dis-
ease. Among HIV infected individuals under HAART, 
the increased longevity may facilitate emergence of 
chronic liver disease which is often a cause of increased 
Fig. 1 A bayesian rooted phylogenetic tree constructed using MrBayesver 3.1.2 of the Cameroon OBI sequences from HBV/HIV co-infected 
individuals. Twenty-eight global sequences obtained from GenBank were included to support tree topology and genotype identification. The ten 
viruses characterised in this study are named with a prefix BM and highlighted in blue at the taxa
Fig. 2 Amino acid alignment of the RT domain (aa 161–213) of the P gene of HBV/HIV co-infected individuals from Cameroon. The Cameroon 
samples are named with a prefix BM and the drug resistance conferring mutations V173L, L180M, and M204V/I are shown. The numbering on top 
indicates the amino acid position
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morbidity and mortality. A significant proportion of 
this burden may be attributed to occult hepatitis B virus 
infection since it has been shown to have hepatopatho-
genic potential. Furthermore, HAART creates immune 
reconstitution that can result in immune mediated liver 
injury and elevation of liver enzymes [17]. This may easily 
be misclassified as HAART-associated liver toxicity.
In this study, we have found a 5.9% prevalence of OBI 
among a group of HIV positive individuals in Cameroon 
and no significant association between the studied demo-
graphic parameters and risk factors of the participants 
and OBI was found.
The prevalence of OBI in this study is similar to the 
5.9% found among HIV individuals in Sicily, Italy [18]. 
However, the observed prevalence is slightly lower than 
the 6.9 and 9.8% reported in Yaoundé, Cameroon and 
Khartoum, Sudan respectively [12, 19]. It should be noted 
however that the prevalence of OBI is dependent on the 
sensitivity of the DNA assay used, demography and the 
population studied [7]. Thus, the Sudan study used a 
more sensitive real time PCR method compared to the 
conventional PCR method used in this study. We propose 
that the difference in prevalence with the Yaoundé study 
may be due to demographics. Among HIV patients, sev-
eral studies conducted worldwide have reported preva-
lence of OBI ranging from 0% to more than 90% [20, 21].
The current study did not find any association between 
OBI and the studied variables. This finding has also been 
made among Cuban HIV patients [22]. Generally, previ-
ous studies have made conflicting findings regarding fac-
tors associated with OBI. For example, Stuart et al. [20] 
have reported a significant association between low CD4 
and OBI among HIV patients while other studies have 
not made this finding [22, 23]. Perhaps this may be due to 
the different diagnostic algorithms used to define OBI in 
the various studies.
Slightly more than half (52.6%) of the OBI positive indi-
viduals were anti-HBc positive, while 45% were anti-HBs 
positive. Our findings on the anti-HBc status is consist-
ent with several studies that indicate the role of the anti-
HBc profile as the most common serological surrogate of 
OBI although higher prevalence of anti-HBc alone does 
not necessarily reflect significantly higher frequency 
of OBI [24, 25]. Dual anti-HBc and anti-HBs reactivity 
was observed in 2 (20%) of the samples. Additionally, we 
identified six OBI positive individuals with no serologic 
evidence of infection (negative for HBsAg, anti-HBc, 
and anti-HBs). This is an indication that occult HBV 
can occur either in patients with serological evidence of 
past “apparently resolved” HBV infection, or also in indi-
viduals with no evident history of exposure to HBV [25]. 
Indeed this finding has epidemiological implications in 
that the burden of HBV in Cameroon, often determined 
by serological assays, is significantly underestimated. 
This ‘silent’ infection also has clinical implications since 
it leads to an increased risk of hepatocellular carcinoma 
[26].
The ten HBV strains sequenced in this study showed 
the circulation of both genotype E and A with genotype E 
predominating. Our findings are in agreement with pre-
vious studies in Cameroon that have documented the cir-
culation of these two genotypes [12, 27]. Drug resistant 
patterns indicate that three of the strains had mutations 
associated with resistance to lamivudine, telbivudine and 
entecavir. Further, that the individuals harboring viruses 
with these mutations were all lamivudine experienced. 
Importantly though, none of the viruses harbored muta-
tions associated with tenofovir and adefovir resistance. 
This finding is in agreement with the recommendation 
to include tenofovir as part of HAART among HIV/HBV 
co-infected patients [28]. Regarding mutations in the “a” 
determinant of the S gene, majority of the viruses had a 
G159A mutation. In addition, all the viruses had 127Lin 
this region. The 127L mutation has previously been asso-
ciated with OBI [29], while the role of G159A in OBI is 
unclear.
The findings in this study should be interpreted in the 
light of several limitations. First, the HBV viral loads 
which are also often used as a marker of OBI were not 
available. Secondly, the study utilized a qualitative and 
not quantitative ELISA format, thus antibody titres were 
not determined. Thirdly, owing to resource constraints 
only 50% of the OBI positive samples were sequenced 
and lastly, the lack of liver enzyme levels precludes our 
ability to correlate the results reported here with clinical 
outcomes.
Conclusion
In conclusion, we report a 5.9% prevalence of OBI among 
HIV infected individuals in Cameroon and the domi-
nance of HBV genotype E. We also show the occurrence 
of OBI in the absence of any serologic evidence of infec-
tion; and the presence of mutations associated with 
lamivudine drug resistance in the study cohort. Fur-
ther prospective studies in a larger cohort are needed to 
determine the clinical implications of OBI in this region.
Additional file
Additional file 1: Figure S1. A representation gel showing amplified 
HBV DNA from HBsAg negative plasma. Lane L is a 100 bp molecular 
weight marker. Expected DNA band sizes of 366 bp were readily detected 
for samples on lanes 2, 5, 7, 8, 10–14. Lane P is a positive control obtained 
from the PCR optimization process and confirmed by sequencing. Lane N 
is a negative control (sterilized distilled water used as template).
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